Hibor

Active Ingredient:: Bemiparin Sodium
Origin:: EU

Hibor (Bemiparin Sodium)

Q: What type of medication is Hibor?

Hibor is a prescription‑only subcutaneous injection that contains the low molecular weight heparin bemiparin sodium, used as an anticoagulant.

Q: How does bemiparin sodium differ from unfractionated heparin?

Bemiparin sodium is a low molecular weight heparin with a more predictable pharmacokinetic profile, primarily inhibiting factor Xa and providing anticoagulation with fewer monitoring requirements compared with unfractionated heparin.

Q: In which surgical patients is Hibor commonly prescribed?

Hibor is often prescribed for patients undergoing orthopedic procedures such as hip or knee replacement, as well as major abdominal or pelvic surgeries where the risk of postoperative venous thromboembolism is elevated.

Q: Can Hibor be used to treat an existing deep vein thrombosis?

Yes, bemiparin sodium is indicated for the treatment of acute deep vein thrombosis and pulmonary embolism, helping to prevent clot extension and new clot formation.

Q: What are the most frequent side effects of Hibor?

The most common adverse reactions include injection‑site erythema, pain, induration, minor bleeding such as nosebleeds or bruising, and occasional gastrointestinal discomfort.

Q: What serious complications should patients be warned about?

Serious complications can include major hemorrhage (including intracranial bleeding), expanding hematomas, heparin‑induced thrombocytopenia, and severe allergic reactions such as anaphylaxis.

Q: Is dose adjustment needed for patients with kidney problems?

Patients with severe renal impairment (creatinine clearance below 30 mL/min) may require dose adjustment because low molecular weight heparins are cleared renally.

Q: Should Hibor be stopped before surgery?

Yes, Hibor should be discontinued prior to procedures that carry a high bleeding risk, and the timing should be coordinated with the surgeon and anesthesiologist.

Q: Can Hibor be taken together with aspirin?

Concurrent use of aspirin or other NSAIDs can increase the risk of minor bleeding and should be evaluated carefully; clinicians often use caution when combining these agents.

Q: Is Hibor safe to use during pregnancy?

Safety data for bemiparin sodium in pregnancy are limited, so the risk‑benefit profile should be assessed by a healthcare professional before use in pregnant or breastfeeding women.

Hibor is a subcutaneous injection that contains the low molecular weight heparin bemiparin sodium; the product is supplied in an unspecified strength and is marketed in the European Union as a prescription‑only anticoagulant. It belongs to the therapeutic class of anticoagulants and works by enhancing antithrombin III activity. Hibor is administered under medical supervision to help prevent and treat thrombotic conditions in patients at risk.

Manufacturer / TM Owner

Laboratorios Farmacéuticos Rovi, S.A

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Hibor is indicated for several clinical situations where inhibition of clot formation is required.

Prevention of venous thromboembolism (VTE) in patients undergoing orthopedic surgery such as hip or knee replacement.
Treatment of acute deep vein thrombosis (DVT) and pulmonary embolism (PE).
Prophylaxis of thromboembolic events in patients with limited mobility after major abdominal or pelvic surgery.
Use in patients with a high risk of postoperative clotting when mechanical methods are insufficient.
Management of clotting risk in certain medical conditions where anticoagulation is recommended.

How It Works

Bemiparin sodium is a low molecular weight heparin that binds to antithrombin III, markedly increasing its ability to inactivate factor Xa and, to a lesser extent, thrombin (factor IIa). By accelerating the inhibition of these key enzymes in the coagulation cascade, the drug reduces the generation of fibrin and thereby limits clot propagation. This selective inhibition provides anticoagulant activity with a more predictable pharmacokinetic profile compared with unfractionated heparin.

Side Effects

Like other anticoagulants, bemiparin sodium may be associated with adverse reactions that range from mild to severe.

Common

Injection site reactions such as erythema, pain, induration, or localized swelling.
Minor bleeding events including epistaxis, gum bleeding, bruising, or mild gastrointestinal bleeding.
Gastrointestinal discomfort or nausea.
Transient elevation of liver enzymes.
Localized warmth at the injection site.

Serious

Major hemorrhage, including intracranial or gastrointestinal bleeding.
Expanding hematoma at the injection site.
Thrombocytopenia, especially heparin‑induced thrombocytopenia (HIT).
Allergic reactions such as urticaria, angioedema, or anaphylaxis.
Spontaneous bleeding from mucosal surfaces.
Severe systemic allergic response leading to anaphylactic shock.

Precautions & Warnings

Before initiating therapy with Hibor, clinicians should evaluate patient-specific factors that may increase the risk of bleeding or other complications.

Known hypersensitivity to bemiparin sodium or any component of the formulation.
Active major bleeding or a high risk of uncontrolled hemorrhage.
Severe renal impairment (creatinine clearance <30 mL/min) because clearance of low molecular weight heparins is reduced.
Concomitant use of other anticoagulants, antiplatelet agents, or thrombolytics.
Pregnancy and breastfeeding status, as safety data are limited.
History of heparin‑induced thrombocytopenia (HIT).
Planned neuraxial anesthesia or spinal puncture, which requires careful timing.

Avoid Interactions

Bemiparin sodium can interact with several medicines, potentially altering its anticoagulant effect or increasing bleeding risk.

Avoid

Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants) or high‑dose antiplatelet drugs.
Systemic thrombolytic agents such as alteplase or streptokinase.

Use with caution

Non‑steroidal anti‑inflammatory drugs (NSAIDs) and aspirin, which may increase minor bleeding.
Selective serotonin reuptake inhibitors (SSRIs) or other drugs affecting platelet function.
Medications that impair renal function, potentially reducing bemiparin clearance.
Herbal supplements with anticoagulant properties, such as ginkgo biloba or garlic.

Frequently Asked Questions

Hibor is a prescription‑only subcutaneous injection that contains the low molecular weight heparin bemiparin sodium, used as an anticoagulant.

Bemiparin sodium is a low molecular weight heparin with a more predictable pharmacokinetic profile, primarily inhibiting factor Xa and providing anticoagulation with fewer monitoring requirements compared with unfractionated heparin.

Hibor is often prescribed for patients undergoing orthopedic procedures such as hip or knee replacement, as well as major abdominal or pelvic surgeries where the risk of postoperative venous thromboembolism is elevated.

Yes, bemiparin sodium is indicated for the treatment of acute deep vein thrombosis and pulmonary embolism, helping to prevent clot extension and new clot formation.

The most common adverse reactions include injection‑site erythema, pain, induration, minor bleeding such as nosebleeds or bruising, and occasional gastrointestinal discomfort.

Serious complications can include major hemorrhage (including intracranial bleeding), expanding hematomas, heparin‑induced thrombocytopenia, and severe allergic reactions such as anaphylaxis.

Patients with severe renal impairment (creatinine clearance below 30 mL/min) may require dose adjustment because low molecular weight heparins are cleared renally.

Yes, Hibor should be discontinued prior to procedures that carry a high bleeding risk, and the timing should be coordinated with the surgeon and anesthesiologist.

Concurrent use of aspirin or other NSAIDs can increase the risk of minor bleeding and should be evaluated carefully; clinicians often use caution when combining these agents.

Safety data for bemiparin sodium in pregnancy are limited, so the risk‑benefit profile should be assessed by a healthcare professional before use in pregnant or breastfeeding women.

Routine laboratory monitoring is generally not required due to the predictable effect of bemiparin, but clinicians may check platelet counts and assess for signs of bleeding, especially in high‑risk patients.

Hibor should be stored in a cool, dry place away from direct sunlight and protected from freezing; the specific storage conditions are provided in the product labeling.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 20 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.